NasdaqGS:MRNABiotechs
Moderna (MRNA) Is Up 11.2% After Lowered 2025 Forecast and Pipeline Updates Is the Growth Story Intact?
In the past week, Moderna reported third quarter financial results showing a year-over-year revenue decrease to US$1.02 billion and a net loss of US$200 million, alongside a lowered full-year 2025 revenue forecast and reduced R&D expense guidance.
Moderna also discontinued its CMV vaccine program due to lack of efficacy and reported progress in regulatory approvals for new respiratory vaccines, which may influence its future product pipeline.
We'll explore how Moderna's revised 2025 revenue...